

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of a combination consisting of
(a) silibinin or a salt thereof
and
(b) α -lipoic acid or a salt thereof,
and a pharmaceutical carrier an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent for each (a) and (b),
wherein each of (a) and (b) are administered to said subject by inhalation in a simultaneous, separate, or timed manner.

Claim 2. (Previously Presented) The method according to claim 1, wherein said subject is a human patient and the dose of said α -lipoic acid or a salt thereof is between 30 and 1800 mg/d.

Claim 3. (Previously Presented) The method according to Claim 1, wherein said subject is a human patient and the dose of said silibinin or a salt thereof is between 20 and 1600 mg/d.

Claim 4. (Cancelled)

Claim 5. (Currently Amended) A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of a combination consisting of
(a) silibinin or a salt thereof, optionally together with an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent; and
(b) α -lipoic acid or a salt thereof, optionally together with an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent; and
(c) an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent;

wherein each of (a) and (b), (b) and (c) are administered to said subject by inhalation in a simultaneous, separate, or timed manner.

Claim 6. (Previously Presented) The method according to Claim 1, wherein each of (a) and (b) is presented in the form of an aerosol.

Claim 7. (Currently Amended) The method according to Claim 1, wherein silibinin or a salt thereof and the α -lipoic acid or a salt thereof ~~is~~ are presented in a single formulation.

Claim 8. (Previously Presented) The method according to Claim 1, wherein silibinin or a salt thereof and the α -lipoic acid or a salt thereof are presented in separate formulations.

Claim 9. (Cancelled)

Claim 10. (Currently Amended) The method according to Claim 7 [[4]], wherein the silibinin ~~or a salt thereof~~ and the α -lipoic acid ~~or a salt thereof~~ are presented in a single formulation.

Claim 11. (Currently Amended) The method according to Claim 8 [[4]], wherein ~~an~~ the silibinin ~~or a salt thereof~~ and the α -lipoic acid ~~or a salt thereof~~ are presented in separate formulations.

Claim 12. (Currently Amended) The method according to Claim 1, wherein the combination consists of

(a) silibinin and

(b) α -lipoic acid,

and an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent for each (a) and (b).

Claim 13. (Previously Presented) The method according to claim 2, wherein the dose of α -lipoic acid or a salt thereof is between 200 and 600 mg/d.

Claim 14. (Previously Presented) The method according to claim 3, wherein the dose of silibinin or a salt thereof is between 300 and 800 mg/d.

Claim 15. (Previously Presented) The method according to Claim 1, wherein said subject is a human patient and the dose of said silibinin or a salt thereof is between 20 and 1600 mg/d and the dose of said α -lipoic acid or a salt thereof is between 30 and 1800 mg/d.